Wong S
Brain and Cognition Discovery Foundation, Toronto, Canada; Poul Hansen Family Centre for Depression, Krembil Research Institute, University Health Network, Toronto, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada. Electronic address: sabrinal.wong@mail.utoronto.ca.
ArticleDMT
Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review.
ArticleKetamine
Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.
ArticleKetamine
The effect of ketamine on mitochondrial bioenergetics, viability, and function: A systematic review.
ArticleKetamine
The effect of the Apollo Neuro device on anxiety among participants who underwent ketamine assisted therapy: A non-randomized, observational cohort study
ArticlePsilocybin
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.
ArticleKetamine
Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review.
ArticleMDMA
The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.
ArticleKetamine
Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.
ArticleKetamine
Effect of ketamine on reward processing in depressive disorders: a systematic review of neuroimaging studies.
ArticlePsilocybin
The combination of exercise and psychedelics for the treatment of major depressive disorder.
ArticleKetamine
The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review.
ArticleKetamine
The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.
ArticlePsilocybin
Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.
ArticleKetamine
Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?
ArticleKetamine
A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?
ArticlePsilocybin
The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence.
ArticleKetamine
Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review.
ArticleMDMA
Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.
ArticleKetamine
The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review.
ArticleKetamine
A Systematic Review of the Effects of N-Methyl-D-Aspartate Receptor Antagonists on Pancreatic Islets.
ArticlePsilocybin
Biological markers of treatment response to serotonergic psychedelic therapies: a systematic review.
ArticleKetamine
The effect of the Apollo Neuro device on anxiety among participants who underwent ketamine assisted therapy.
ArticlePsilocybin
Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.
ArticlePsilocybin
Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.
ArticlePsychedelics
Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments.
ArticleKetamine
A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.
ArticleKetamine
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications.
ArticleKetamine
The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.
ArticlePsychedelics
Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.
ArticlePsychedelics
Emergency Department Visits Involving Hallucinogen Use and Risk of Schizophrenia Spectrum Disorder.
ArticleKetamine
Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.
ArticleKetamine
Functional Connectivity Between Glutamate Receptor Antagonism and Insulin Pathways: Implications for Modeling Mechanism of Action of Ketamine/Esketamine and Dextromethorphan in Depression Treatment.
ArticleKetamine
A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.
ArticleKetamine
Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.
ArticlePsilocybin
Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.
ArticlePsilocybin
A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.
ArticlePsilocybin